Patients with progressive metastatic(or recurrent) differentiated thyroid carcinoma that either do not take up radioioidine or are unresponsive to continued radioiodine therapy can be selected for somatostatin-receptor scinti-graphy(SRS) and high-dose peptide receptor radionuclide therapy(PRRT).PRRT with the β-particle-emitting ra-dionuclides yttrium-90(90Y) and lutetium-177(177Lu) gives the best results in terms of objective tumor response.Promising and novel radiolabeled somatostatin analogs used in the diagnosis and treatment of thyroid cancer are also discussed.